Shi, Y. , Li, Y. , Chen, W. , Zhang, M. , Qian, D. , Li, T. , Dai, Y. and Li, G. 2024. Cost-effectiveness analysis of Sintilimab vs. Docetaxel as the second-line therapy of squamous non-small cell lung cancer in China. Health Decision. 2, S1 (Jul. 2024). DOI:https://doi.org/10.54844/hd.2024.0007.